CRISPR Therapeutics AGCRSPNASDAQ

Revenue (LTM)

$4M

-90.0% YoY

Net Income (LTM)

$-582M

-58.8% YoY

Free Cash Flow

$-346M

Revenue CAGR (5Y)

+37.3%

Marginsimproving

FCF($0.3B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	913	0↓100.0%	370↑84762.4%	35↓90.5%	4↓90.0%
Gross Profit	812	-110↓113.5%	240↑318.3%	-75↓131.4%	-229↓204.9%
Operating Income	374	-673↓280.2%	-223↑66.9%	-467↓109.7%	-568↓21.8%
Net Income	378	-650↓272.2%	-154↑76.4%	-366↓138.4%	-582↓58.8%
EBITDA	391	-649↓265.8%	-203↑68.8%	-447↓120.7%	-549↓22.7%
EPS Diluted	4.70	-8.36↓277.9%	-1.94↑76.8%	-4.34↓123.7%	-6.47↓49.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	923	212↓77.0%	389↑83.8%	298↓23.4%	355↑19.1%
Total Current Assets	2,418	1,853↓23.3%	1,908↑3.0%	1,937↑1.5%	1,986↑2.5%
Total Assets	2,752	2,243↓18.5%	2,230↓0.6%	2,242↑0.6%	2,265↑1.0%
Total Current Liabilities	120	121↑1.0%	109↓10.2%	88↓19.3%	149↑69.9%
Total Liabilities	352	368↑4.3%	347↓5.7%	310↓10.6%	343↑10.8%
Total Equity	2,399	1,875↓21.8%	1,883↑0.4%	1,932↑2.6%	1,922↓0.5%
Total Debt	225	244↑8.4%	239↓2.2%	224↓6.3%	395↑76.5%
Net Debt	-698	32↑104.6%	-151↓569.4%	-75↑50.6%	40↑153.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	539	-496↓192.0%	-260↑47.5%	-143↑45.2%	-345↓141.7%
Capital Expenditure	-82	-37↑54.5%	-9↑74.5%	-2↑79.9%	-1↑51.9%
Free Cash Flow	457	-533↓216.5%	-270↑49.4%	-145↑46.4%	-346↓139.1%
Stock-Based Comp	102	98↓4.3%	81↓17.3%	87↑6.8%	72↓16.3%
Net Change in Cash	-246	-716↓191.6%	178↑124.8%	-91↓151.4%	49↑154.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance